FDA Commissioner: Patient Safety Must Be Prioritized Over Job Creation
Dr. Hamburg was joined by Paul Glover of Health Canada and Guido Rasi of the European Medicines Agency at the Drug Information Association's 48th annual meeting.
The FDA was recently scrutinized by Congressional members who believe the agency has impeded job creation by shutting down plants with quality control problems. Dr. Hamburg stressed quality concerns, such as glass shards and metal fractures in tobacco products, could not be ignored by the FDA and other regulators.
Mr. Glover added a universal reporting mechanism could more quickly alert regulators about adverse events and promote patient safety around the world.
More Articles on Patient Safety:AHRQ 2011 State Snapshots Spotlight Healthcare Quality, Population Health
© Copyright ASC COMMUNICATIONS 2016. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.
- 4 GI physicians in the news — July 29, 2016
- Takeda Pharmaceutical plans $725M R&D redesign: 5 things to know
- Dr. James Cottrell wins Arthur Ashe Institute for Urban Health's leadership award: 5 notes
- Anthem to add 9 ACA exchanges if Cigna deal passes: 4 takeaways
- Florida marks 1st state of local Zika mosquito transmission; 4 people infected — 5 things to know